Protein Kinase Inhibitors: all 15,766 studies that test it

Page 3 of 158. Open to participants first (2,605), then studies with results posted, then the rest; newest registration first within each.

• Trilaciclib Combined With Immunochemotherapy for R/M HNSCCNot yet recruitingNCT07679997Phase 2
• Phase I Trial of Pacritinib in Combination With Venetoclax and Azacitidine for the Treatment of Accelerated and Blast Phase Myeloproliferative NeoplasmsNot yet recruitingNCT07679334Phase 1
• Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety.Not yet recruitingNCT07679269Phase 2
• The Safety and Efficacy of Upadacitinib in Refractory Autoimmune Related Cholangitis and Atopic Dermatitis With Moderate to Severe ItchingNot yet recruitingNCT07678645Phase 2
• Orelabrutinib Combined With Induction Therapy Followed by Sequential Monotherapy Maintenance in MCD Subtype Diffuse Large B-cell LymphomaNot yet recruitingNCT07677813Phase 2
• NIMBLE-CRC: NeoImmunoModulation Before Leveraging Excision in Colorectal Rectal CancerNot yet recruitingNCT07677579Phase 2
• A Study to Learn How the Study Medicine Called Atirmociclib is Handled by the Body in People With Normal Liver Function and Different Levels of Liver DiseaseRecruitingNCT07677358Phase 1
• A Study of BEBT-908 in Combination With Chemotherapy in Patients With Previously Untreated Peripheral T-Cell Lymphoma (PTCL)Not yet recruitingNCT07676175Phase 2
• A Phase 2 Trial Of The Combination Of Zanubrutinib, Sonrotoclax, And Obinutuzumab For Patients With Treatment-Naïve Chronic Lymphocytic LeukemiaNot yet recruitingNCT07674810Phase 2
• Nemtabrutinib With CAR T Therapy in Relapsed/Refractory Mantle Cell LymphomaRecruitingNCT07673367Phase 2
• Perioperative Ursodeoxycholic Acid for Renal Protection in Adults Undergoing Partial Nephrectomy for Renal TumorsRecruitingNCT07672860Phase 2
• Human Mass Balance Study of [14C] Ontunisertib in Healthy VolunteersRecruitingNCT07672574Phase 1
• A Study of MRD-Guided Zanubrutinib Plus Sonrotoclax in Treatment-Naïve, High-Risk CLL/SLL PatientsRecruitingNCT07671378Phase 2
• Trial of Delgocitinib 20 mg/g Cream in Subjects With Frontal Fibrosing Alopecia (FFA)Not yet recruitingNCT07671157Phase 2
• Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib as First-Line Therapy for Advanced HER2-Positive/HER2-Low Biliary Tract CancerRecruitingNCT07670273Phase 2
• Upadacitinib in Treatment of JAK/STAT Pathway Disorders With Activating MutationsNot yet recruitingNCT07670156Phase 1/2
• TPO-RA Plus Baricitinib vs. TPO-RA for ITPNot yet recruitingNCT07669675Phase 2
• A Phase II Clinical Study of the Efficacy and Safety of Culmerciclib Rechallenge in HR-positive, HER2-negative Breast Cancer Patients With Resistance to First-line Endocrine Therapy.RecruitingNCT07666555Phase 2
• An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HSRecruitingNCT07665437Phase 3
• Effect of Ursodeoxycholic Acid Supplementation on Liver Regeneration in Adult Living Donor Liver Transplant (LDLT) Recipients.Not yet recruitingNCT07664020Not applicable
• Camrelizumab With Famitinib for Patients With Rare Head and Neck MalignanciesRecruitingNCT07662681Phase 1/2
• Ventricular mTOR Inhibition to Prevent Hydrocephalus After Brain HemorrhageNot yet recruitingNCT07662174Phase 1/2
• Opzelura Experience StudyNot yet recruitingNCT07661979Phase 4
• A Prospective Study of Firmonertinib as First-line Adaptive Therapy Guided by Dynamic ctDNA (MRD) Changes in Locally Advanced or Metastatic EGFR-mutated Non-small Cell Lung CancerNot yet recruitingNCT07661173Phase 2
• Sirolimus in Patients With Systemic Lupus Erythematosus-Associated Immune ThrombocytopeniaRecruitingNCT07657793Phase 2/3
• Low- vs High-Dose Sirolimus With Prednisolone for KHE and KMPRecruitingNCT07656909Phase 2/3
• Sintilimab Plus Gossypol Acetate in Advanced Colorectal CancerNot yet recruitingNCT07656766Phase 2
• Vebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non-small Cell Lung Cancer and High PD-L1 ExpressionRecruitingNCT07655622Phase 1/2
• Precision Medicine for Immunotherapy-Resistant Advanced Esophageal CancerNot yet recruitingNCT07653451Phase 2/3
• IN10018 in Combination With Dalpiciclib for Progressive MeningiomasRecruitingNCT07652762Phase 1
• A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast CancerRecruitingNCT07647328Phase 3
• Exploratory Study on Toripalimab and Anlotinib Combined With Standard Chemotherapy for Refractory Dermatofibrosarcoma ProtuberansNot yet recruitingNCT07646080Phase 2
• Human ADME Study of [14C]-AZD1390Not yet recruitingNCT07643870Phase 1
• Belumosudil With Ruxolitnib as Third Line Therapy for Chronic Graft Versus Host Disease (cGvHD)Not yet recruitingNCT07643025Phase 2
• A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09)RecruitingNCT07642024Phase 2/3
• Preoperative Durvalumab, Cisplatin, Gemcitabine With or Without Futibatinib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangiocarcinoma, OPTIC TrialNot yet recruitingNCT07639528Phase 2
• Testing Mosunetuzumab Alone, With Zanubrutinib, or With Polatuzumab Vedotin for Treating Marginal Zone Lymphoma That Came Back or Didn't Get Better With TreatmentNot yet recruitingNCT07638722Phase 2
• Acalabrutinib Maleate and Bortezomib for Patients With HLA AntibodiesNot yet recruitingNCT07635511Phase 3
• Pyrotinib Plus Trastuzumab and Chemotherapy for HER2-Positive Early Breast CancerRecruitingNCT07635342Phase 2
• Elacestrant With Everolimus for the Treatment of Recurrent Advanced or Metastatic ER-Positive Endometrial CancerNot yet recruitingNCT07634601Phase 2
• Vertebrobasilar Dolichoectasia Treatment With SirolimusNot yet recruitingNCT07634120Phase 2
• A Phase 1b, Open-Label Study Of REC-617, A Selective CDK7 Inhibitor, In Patients With Metastatic Or Unresectable RB1-Negative Leiomyosarcoma After Prior Systemic TherapyRecruitingNCT07633756Phase 1
• Lomustine Combined With Anlotinib as Interventional Therapy for Extensive-stage Small Cell Lung Cancer Resistant to Second-line and Above TreatmentNot yet recruitingNCT07632209Phase 2
• Camrelizumab Combined With Famitinib Malate and Chemotherapy for Treatment of Recurrent/ Metastatic Cervical CancerNot yet recruitingNCT07627620Phase 2
• Anlotinib + Benmelstobart vs Surgery for Patients With Localized Renal Cell Carcinoma Scheduled to Undergo Partial NephrectomyNot yet recruitingNCT07627464Phase 2
• Efficacy and Safety of Anlotinib Combined With Bemocizumab for Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma(ESCC)RecruitingNCT07627347Not applicable
• Fixed Duration Treatment With Combined Pirtobrutinib and Short Course Immuno-chemotherapy in Fit Patients With Previously Untreated Symptomatic Chronic Lymphocytic Leukemia (CLL).Not yet recruitingNCT07624799Phase 2
• Zanzalintinib Efficacy Post Pluvicto® in Chemotherapy Naïve Metastatic Castration Resistant Prostate CancerNot yet recruitingNCT07623460Phase 2
• Effects of Short-term Perioperative Daidzein Intervention on Liver Histopathology in Patients With MASLDNot yet recruitingNCT07623044Phase 2
• Pirtobrutinib Maintenance After CAR-T Therapy in Relapsed or Refractory B-Cell LymphomaNot yet recruitingNCT07622784Phase 2
• Firmonertinib in Perioperative Treatment of Resectable Stage II-IIIB EGFR-mutated Lung AdenocarcinomaNot yet recruitingNCT07622706Phase 2
• A Single-arm, Multicenter Clinical Study of Fruquintinib Combined With Serplulimab and Chemotherapy as First-line Treatment for Patients With RAS/BRAF-mutated Advanced Colorectal CanceNot yet recruitingNCT07622550Phase 2
• Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored StudyEnrolling by invitationNCT07620574Phase 3
• Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal AdenocarcinomaRecruitingNCT07619521Phase 1/2
• A Study of Tepotinib and Ivonescimab in People With Non-Small Cell Lung CancerRecruitingNCT07619339Phase 1
• A Phase II Study of Zongertinib Plus Fulvestrant in Participants With HR-positive/HER2-negative Advanced Breast Cancer Harboring HER2 Mutations.Not yet recruitingNCT07619066Phase 2
• Neoadjuvant Dalpiciclib + AI → SHR-A1811 for HR+/HER2-Low Breast CancerNot yet recruitingNCT07618923Phase 2
• A Multicenter, Randomized, Open-label, Controlled Study of HAIC Combined With Camrelizumab and Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma With High-risk Recurrence FactorsNot yet recruitingNCT07618546Not applicable
• A Phase ll, Interventional, Single-arm Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib and Fulvestrant in Chinese Patients With PIK3CA-mutant, HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer.Not yet recruitingNCT07618390Phase 2
• Study of DCC-2618 in Patients With GIST After at Least 3 Prior TreatmentsRecruitingNCT07618377Phase 1
• Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Japanese Adults With Severe Alopecia AreataRecruitingNCT07617597Phase 3
• ATRN-119 in Combination With Decitabine in Patients With TP53-Mutated AML or Higher-Risk MDSNot yet recruitingNCT07617363Phase 1
• AQUA07 in Patients With ALK-Positive Non-Small Cell Lung CancerRecruitingNCT07617337Phase 1
• Efficacy and Safety of Culmerciclib Plus Aromatase Inhibitors in a Response-Adapted Neoadjuvant Strategy for Highly Proliferative ER-Positive/HER2-Negative Breast CancerRecruitingNCT07616453Phase 2
• Fovinaciclib Plus Aromatase Inhibitors and Dual HER2 Blockade in a Response-Adapted Neoadjuvant Strategy for HR-Positive/HER2-Positive Early Breast CancerRecruitingNCT07616427Phase 2
• Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell DiseaseRecruitingNCT07616154Phase 2
• Neoadjuvant Anlotinib and Epirubicin for T4 Sinonasal Adenoid Cystic CarcinomaNot yet recruitingNCT07616141Phase 2
• Pyrotinib and Trastuzumab Combined With Dalpiciclib Versus Combined With Docetaxel in Advanced HER2-Positive Breast CancerRecruitingNCT07615751Phase 3
• HRX215, A First Generation MKK4 Inhibitor Drug, for the Treatment of Patients With Colorectal Liver Metastasis After Undergoing a Portal Vein EmbolizationNot yet recruitingNCT07612007Phase 2
• Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast CancerRecruitingNCT07610720Phase 2
• Retlirafusp Alfa Combined With Apatinib and Nab-Paclitaxel as Second-line Treatment for Gastric or Gastroesophageal Junction CancerNot yet recruitingNCT07610629Phase 2
• A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell MalignanciesRecruitingNCT07609862Phase 1/2
• Hypofractionated Chemoradiotherapy With Tislelizumab and Surufatinib for Unresectable Stage III NSCLCRecruitingNCT07609121Phase 2
• Efficacy and Safety of Polatuzumab Vedotin in Combination With Zanubrutinib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma of the MCD/BN2/N1 SubtypesRecruitingNCT07608978Phase 2
• JAK Signaling in Depression and Cognition in Male Football PlayersRecruitingNCT07608796Phase 2
• Phase II Trial of Zanzalitinib in Patients With Metastatic Castration Resistant Prostate CancerNot yet recruitingNCT07608718Phase 2
• Neoadjuvant PD-L1 Inhibitor Plus Anlotinib for Kidney Preservation in Complex Renal Cell CarcinomaNot yet recruitingNCT07602101Phase 2
• Harmony-HHT: ATV-1601 in Participants With Hereditary Hemorrhagic Telangiectasia (HHT)RecruitingNCT07601425Phase 1/2
• Real-world Study of Pyrotinib-containing Regimens of Advanced HER2-positive Breast CancerRecruitingNCT07600164Phase 4
• Modulation of the Immune System in Down Syndrome for Improved Outcomes and Neurodevelopment - 1RecruitingNCT07598643Phase 2
• Efficacy and Safety of Ruxolitinib Cream in Chinese Children Aged 2-11 Years With Non-segmental VitiligoNot yet recruitingNCT07595939Phase 3
• AI-Driven Treatment Strategy vs Pola-R-CHP in Untreated LBCLNot yet recruitingNCT07594899Phase 2
• Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal AdenocarcinomaNot yet recruitingNCT07594548Phase 1
• Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer After Progression on or Following First-Line Immunotherapy MaintenanceRecruitingNCT07594015Phase 2
• daGOAT-Guided Prevention of Severe aGVHD After Allo-HSCTNot yet recruitingNCT07588945Phase 3
• A Trial of Upadacitinib for Non-responsive Eosinophilic EsophagitisRecruitingNCT07588568Phase 2
• Vaccination Response Modulation With a Targeted Rapamycin Protocol StudyNot yet recruitingNCT07587801Phase 2
• A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLCRecruitingNCT07586202Phase 2
• A Exploratory Study on Untreated Follicular Lymphoma With Orelabrutinib, Tafasitamab, and LenalidomideNot yet recruitingNCT07585747Phase 2
• A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline)RecruitingNCT07585266Phase 3
• The DoHAICs Study Expansion PhaseNot yet recruitingNCT07584018Phase 2
• Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone LymphomaRecruitingNCT07583810Phase 2
• Nintedanib With or Without Dextromethorphan in Patients With Idiopathic Pulmonary Fibrosis (IPF)Not yet recruitingNCT07583589Phase 2
• Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaNot yet recruitingNCT07582159Phase 2
• Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical StudyRecruitingNCT07581834Phase 2
• Sirolimus Pre-conditioning on T Cell Activity and T-cell Engaging Bispecific Antibody Efficacy in Multiple MyelomaRecruitingNCT07581704Phase 1
• Comparison of Methotrexate and Tofacitinib in Chronic Plaque PsoriasisNot yet recruitingNCT07581418Not applicable
• Combining Neo-adjuvant ATR-inhibition With Nodal SBRT for Early-stage Resectable HPV+ OPSCCsNot yet recruitingNCT07578467Phase 1/2
• Zanzalintinib and MO-03 for the Treatment of Metastatic Renal Cell Cancer After Progression on ImmunotherapyNot yet recruitingNCT07578025Phase 2
• Perioperative Trial With IO/TKI for Multi-stage Clear Cell Renal Cell CarcinomaRecruitingNCT07571551Phase 2

← Protein Kinase Inhibitors overview